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Abstract
Background: Despite recent advances in multimodality and multidisciplinary treatment of colorectal liver metastases,
many patients suffer from extensive bilobar disease, which prevents the performance of a single procedure due to an
insufficient future liver remnant (FLR). We present a novel indication for associating liver partition and portal vein ligation
for staged hepatectomy (ALPPS) as a “liver-first” approach when inadequate FLR was faced preoperatively, in a patient
with extensive bilobar liver metastatic disease of colon cancer origin.
Case presentation: A 51-year-old lady was referred to our center due to a stage IV colon cancer with extensive bilobar
liver disease and synchronous colon obstruction. During the multidisciplinary tumor board, it was recommended
to proceed first in a palliative loop colostomy (at the level of transverse colon) operation and afterwards to offer
her palliative chemotherapy. After seven cycles of chemotherapy, the patient was re-evaluated by CT scans that
revealed an excellent response (>30 %), but the metastatic liver disease was still considered inoperable. Moreover,
with the completion of 12 cycles, the indicated restaging process showed further response. Subsequent to a
thorough review by the multidisciplinary team, it was decided to proceed to the ALPPS procedure as a feasible
means to perform extensive or bilobar liver resections, combined with a decreased risk of tumor progression in
the interim.
Conclusions: All in all, ALPPS can offer a feasible but surgically demanding liver-first approach with satisfactory
short-term results in selected patients. Larger studies are mandatory to evaluate short- and long-term results of
the procedure on survival, morbidity, and mortality.
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Background
Despite recent advances in multimodality and multidis-
ciplinary treatment of colorectal liver metastases (CLM),
many patients suffer from extensive bilobar disease,
which prevents the performance of a single procedure
due to an insufficient future liver remnant (FLR). The
latter seems to be the most important deciding factor in
planning for liver resection. Portal vein ligation (PVL) or
embolization (PVE) are standard approaches to induce
liver hypertrophy of the FLR prior to hepatectomy in
primarily non-resectable liver tumors [1].
The associating liver partition and portal vein ligation
for staged hepatectomy (ALPPS) procedure was recently
developed as a feasible means to perform extended liver
resections [2]. It produces rapid, enormous hypertrophy
of the remnant, making previously unresectable lesions
resectable. Indications for ALPPS include any extensive
liver resection with inadequate FLR [3].
Recent data are equivocal about the application of
this technique in CLM as a feasible, efficient, and safe
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alternative to two-stage hepatectomy in terms of mor-
bidity, oncological outcomes, and disease-free survival.
A recent study showed that ALPPS is not inferior to
two-stage hepatectomy in terms of intermediate onco-
logical outcomes as well as perioperative morbidity in
patients with CLM [4]. A multi-center study though
demonstrated higher perioperative morbidity rates in
ALPPS group compared to the two-stage hepatectomy
approach, claiming the latter as the standard approach
for performing R0 resection in patients with advanced
CLM and inadequate FLR [5].
There are emerging data of the incorporation of ALPPS
technique in therapeutic strategy in patients with CLM in
order to achieve a macroscopic disease-free state and lead
the patient as soon as possible to the oncological path. An
example of such technique is the simultaneous resection
of the primary colonic tumor with step one of the ALPPS
procedure that may be feasible, safe, and efficient [6].
We present a novel indication for ALPPS as a “liver-
first” approach when inadequate FLR was faced preopera-
tively, in a young patient with an extensive liver metastatic
disease due to a splenic flexure colon cancer.
Case presentation
A 51-year-old lady was referred to our center on 23/09/
14 due to a stage IV colon cancer without any other
major comorbidities. Her past medical history dated
back almost 3 months ago with episodes of abdominal
pain and constipation. Unfortunately, her previous in-
vestigation by colonoscopy showed an obstructing, in-
filtrative grade II adenocarcinoma in the area of splenic
flexure, and the three-phase CT scans of the chest-
abdomen-pelvis also revealed a stage IV disease with
bilobar liver lesions (Fig. 1a).
During the multidisciplinary tumor board, it was recom-
mended to proceed first in a palliative loop colostomy (at
the level of transverse colon) operation and afterwards to
offer her chemotherapy in the palliative setting. Due to
the extensive nature of liver lesions, the disease was ini-
tially evaluated as unresectable.
Further investigation by mutation analysis of exons 2,
3, and 4 of the KRAS and NRAS and exon 15 of the
BRAF gene revealed no mutations. Additionally, tumor
markers’ evaluation revealed CEA = 1.341 ng/ml and CA
19.9 = 7.4 U/ml.
She was initiated on FOLFIRI [Irinotecan 180 mg/m2,
folinic acid 175 mg, 5-fluorouracil (bolus) 400 mg/m2, 5-
fluorouracil 2.400 mg/m2 (48 h pump)] plus cetuximab
500 mg/m2 on day 1, every 2 weeks via port-a-cath.
Afterwards seven cycles of chemotherapy (3/10/14–13/
01/15), the patient was restaged by full body CT scans
performed by the standard three-phase protocol, that re-
vealed an excellent response (>30 %), but liver lesions
were again evaluated as unresectable. In addition, CEA
evaluation showed a marked response (129, 2 ng/ml).
Her restaging by CT chest-abdomen-pelvis scans, MRI
liver (2/4/15) after the completion of 12 cycles of com-
bined chemotherapy, as previously described, showed
further response (>25 %) (Fig. 1b,c). Furthermore, dra-
matic decrease of CEA was also noted (6 ng/ml).
The decision to proceed to the ALPPS procedure as
a feasible means to perform extensive or bilobar liver
resections, combined with decreased risk of tumor
progression in the interim, was made. The first step of
the procedure including partitioning of the right lobe
of the liver with right portal vein ligation was com-
bined with four metastasectomies and two radiofre-
quency ablations (RFA) to the lesions of left lateral
liver parenchyma—for 10 min at 45 W—as well as
with closure of loop colostomy. A diverting loop ileos-
tomy was performed instead in order to avoid major
trauma infection. At this stage, a decision to avoid
portal embolization was made since in that case, the
possibility of inadequate future liver remnant was high
due to the interventions in the left lateral liver and
chemotherapy-induced liver injury.
Fig 1 a Pre-chemotherapy abdominal CT scan showing multiple liver mestastases. b Post-chemotherapy abdominal CT scan showing response to
treatment. c, e Abdominal CT scans showing adequate volume expansion after the step 1 of ALPPS procedure. d Postoperative abdominal CT scan
without evidence of disease recurrence
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In the tenth postoperative day (POD), a new abdom-
inal CT scan was made that revealed adequate volume
expansion of the future liver remnant and we decided to
proceed to the second step of the procedure (Fig. 1d,e).
CT volumetrics on POD 10 showed a total liver volume
of 1690 cc with the left liver estimated to comprise ap-
proximately 40–50 % of the total volume.
The patient was discharged the POD 7 after the sec-
ond step with an almost uneventful postoperative course
except of a minor wound infection that was treated con-
servatively (wound dressing changes three times per
week). On her first postoperative follow-up visit, her
total bilirubin was 1.2 mg/dl and ALT/AST/ALP were
46/37/204 U/l. Of interest, her postoperative liver MRI
showed no new lesions, without differences in the levels
of CEA.
On 6/8/15 a left hemicolectomy was successfully per-
formed. The histopathology report revealed an ypT3ypN2
(6+/14), gr II adenocarcinoma. Afterwards, the patient re-
ceived three more months of combined chemotherapy
(FOLFIRI + cetuximab, q2w, × six cycles) completed. The
subsequent evaluation by CT chest-abdomen-pelvis
scans by the end of December 2015 revealed no evi-
dence of disease.
Operative technique
The operation was divided in two steps. The first con-
sisted of exploratory laparotomy, assessment of resect-
ability with intraoperative ultrasound, and positioning
the tumor in relation to vessels. Four small lesions in left
lateral lobe were resected. The liver was mobilized by
dissecting the ligaments. The right liver lobe was com-
pletely mobilized from the cava vein. Hilar structures
were exposed, and extensive nodal resection was per-
formed. After the right portal vein branch being identi-
fied, it was divided. Right hepatic artery and right
hepatic duct were identified and kept into a vessel loop
(Fig. 2a). Biliary segment IV branch was also identified
and kept into a vessel loop. After that, the hanging man-
euver was performed and both right hepatic and a major
short hepatic vein were also kept in a vessel loop to en-
sure better venous outflow. Finally, total parenchymal
dissection over the hanging maneuver plane at the right of
the falciform ligament was performed using bipolar co-
agulation irrigated with saline solution (CUSA, Harmonic,
Aquamantys). After in situ splitting, the right lobe was
covered by a biomaterial and the abdomen was drained
and closed (Fig. 2b).
The second step of the procedure was completed by
re-laparotomy. After careful adhesiolysis, the right hep-
atic artery, right hepatic duct, and the right hepatic vein
were ligated. The liver resection was completed. The left
lateral lobe was then fixed to the remnant falciform liga-
ment. Finally, a drain was placed at the resection surface
and the abdomen was closed. Since it was the very first
experience of our team on the procedure and because
we performed extensive metastasectomies and ablation
to left lateral, we were conservative and kept the seg-
ment IV.
Discussion
There is emerging literature on extending the indica-
tions for ALPPS as a rescue procedure when inadequate
FLR is faced intraoperatively, during a simultaneous re-
section of colonic primary and liver metastasis [6] or
after failure of PVL/PVE [1].
The current trend for the management of patients
with synchronous colorectal cancer and liver metastatic
disease is the so-called liver-first approach [7]. This
modern policy has evolved as a result of the increasing
evidence supporting preoperative chemoradiotherapy for
rectal cancer as well as due to the view that it is the liver
metastatic disease, rather than the primary cancer, that
gives rise to systemic metastatic disease and defines the
survival [7]. Following systemic chemotherapy, the liver
resection is undertaken as the first operative interven-
tion with the reasoning being that it is the burden of
liver disease that is the likeliest course of subsequent
metastasis [7]. Colorectal cancer resection is reserved as
the second operative step, and for selected patients with
rectal tumors (who have a complete endoscopic and
radiologic response to chemoradiotherapy), there may
then be the option to avoid pelvic surgery altogether [7].
ALPPS is a new two-stage hepatectomy that has par-
tially evaluated postoperative outcomes in patients with
malignant liver disease (primary and metastatic). It seems
that patients with CLM are mostly benefited from this ap-
proach in terms of early postoperative outcomes [8]. It
was recently shown that neoadjuvant chemotherapy sig-
nificantly impairs hypertrophy of the FLR after ALPPS
without impact on either morbidity or in-hospital mortal-
ity [9]. This is of great importance for the preoperative
Fig 2 a Right hepatic artery and right hepatic duct kept into a vessel
loop. b After in situ splitting, the right lobe was covered by a biomaterial
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strategy especially in cases where ALPPS is used as a bail-
out procedure.
As we have previously described, simultaneous right
hemicolectomy and stage I ALPPS could be a feasible op-
tion [6].
All in all, our case stands for a description of a novel
indication of ALPPS as a liver-first approach in a patient
with cancer and extensive liver metastatic disease. To
our knowledge, this is the first performance of the tech-
nique in the Greek Cypriot area with satisfactory results.
Conclusions
All in all, ALPPS can offer a feasible but surgically de-
manding liver-first approach with satisfactory short-term
results in selected patients. Larger studies are mandatory
to evaluate short- and long-term results of the procedure
on survival, morbidity, and mortality.
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